Yang H, Lin XF, Padilla F, Gabriel SD, Heilek G, Ji C, Sankuratri S, deRosier A, Berry P, Rotstein DM. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Bioorg Med Chem Lett 2008;
19:209-13. [PMID:
19014885 DOI:
10.1016/j.bmcl.2008.10.115]
[Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2008] [Revised: 10/21/2008] [Accepted: 10/27/2008] [Indexed: 10/21/2022]
Abstract
Replacement of the cyclic carbamate in our previously disclosed 1-oxa-3,9-diazaspiro[5.5]undecan-2-one template led to the discovery of two novel series of 3,9-diazaspiro[5.5]undecane and undeca-2-one CCR5 antagonists. The synthesis, SAR, and antiviral activities of these two series are described. One compound (32) was found to have attractive combination of antiviral potency, selectivity, and pharmacokinetic profile. The asymmetric synthesis of 32 was also accomplished and both enantiomers were equally potent.
Collapse